Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy

Affiliations

¹ Department of Neurology, Neuromuscular Division, Thomas Jefferson University, Philadelphia, PA, USA; Neuroimmunology Unit, Department of Pathophysiology, National and Kapodistrian University of Athens Medical School, Athens, Greece. Electronic address: marinos.dalakas@jefferson.edu.

Comment

Marinos C Dalakas. Lancet Neurol. 2018 Jan.

. 2018 Jan;17(1):20-21.

doi: 10.1016/S1474-4422(17)30379-4. Epub 2017 Nov 6.

¹ Department of Neurology, Neuromuscular Division, Thomas Jefferson University, Philadelphia, PA, USA; Neuroimmunology Unit, Department of Pathophysiology, National and Kapodistrian University of Athens Medical School, Athens, Greece. Electronic address: marinos.dalakas@jefferson.edu.

No abstract available

Comment on

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. van Schaik IN, et al. Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Lancet Neurol. 2018. PMID: 29122523 Clinical Trial.